Search Within

Andrew D Seidman

  1. "Larry Norton"
Formats
  1. Journal Article (47)
  2. Meeting Abstract (43)
  3. Conference Paper (8)
  4. Correspondence (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (99)
  2. Breast Medicine Service (99)
  3. Department of Medicine (99)
  4. Solid Tumor Oncology Division (99)
  5. Survivorship Research (87)
  6. Behavioral Sciences Service (38)

More Groups

People
  1. Larry Norton (99)
  2. Clifford Hudis (85)
  3. Teresa Gilewski (38)
  4. Violante Currie (31)
  5. Nancy Sklarin (28)
  6. Gabriella D'Andrea-Carlino (27)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2019 (1)
  4. 2018 (2)
  5. 2016 (1)
  6. 2014 (1)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Breast Cancer Research and Treatment (16)
  3. Clinical Cancer Research (8)
  4. Cancer Research (7)
  5. Seminars in Oncology (7)
  6. Cancer Investigation (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. American Association for Cancer Research (17)
  3. Springer (17)
  4. Elsevier Inc. (14)
  5. Informa Healthcare (5)
  6. Oxford University Press (4)

More Publishers

Results (99)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Journal Article

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Cancer Investigation (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Schwartz, M. K.; Ghani, F.; Thiel, R.; Norton, L.; Hudis, C.
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
    Meeting Abstract

    Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Dressler, L.; Muss, H.; Norton, L.; Winer, E.; Hudis, C.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Journal Article

    Dang, C. T.; Dannenberg, A. J.; Subbaramaiah, K.; Dickler, M. N.; Moasser, M. M.; Seidman, A. D.; D'Andrea, G. M.; Theodoulou, M.; Panageas, K. S.; Norton, L.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Journal Article

    Dang, C. T.; D'Andrea, G. M.; Moynahan, M. E.; Dickler, M. N.; Seidman, A. D.; Fornier, M.; Robson, M. E.; Theodoulou, M.; Lake, D.; Currie, V. E.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Bone mineral density and hormone receptor status in patients with newly diagnosed breast cancer, a retrospective assessment
    Meeting Abstract

    Van Poznak, C. H.; Howard, J. E.; Seidman, A. D.; Norton, L.; Hudis, C.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • Serum HER2 extracellular domain (ECD) correlates with HER2 status by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) in metastatic breast cancer (MBC) patients (pts) treated with weekly (W) trastuzumab (H) and paclitaxel (T)
    Meeting Abstract

    Fornier, M. N.; Seidman, A. D.; Schwartz, M. K.; Panageas, K. S.; Norton, L.; Hudis, C. A.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save